Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion.

scientific article

Extreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.CCELL.2015.11.006
P932PMC publication ID4684594
P698PubMed publication ID26678339

P50authorDaniel P CahillQ40711326
Elisabeth M RoiderQ59859356
Dan ZhaoQ79405023
P2093author name stringDavid E Fisher
Keith T Flaherty
Robert E Gerszten
William T Curry
A John Iafrate
Gejing Deng
Shota Tanaka
Andrew S Chi
Tracy T Batchelor
Xu Shi
Jing-Ruey J Yeh
Hiroaki Wakimoto
Yiyun Zhang
Yardena Samuels
Timothy He
Fares Nigim
Dmitri Wiederschain
Kensuke Tateishi
Bailin Zhang
Olivier Bedel
Mara V A Koerner
Lajos V Kemeny
Franziska Loebel
Nina Lelic
Quan Ho
Sudhandra Sundaram
P2860cites workCancer genome landscapesQ22242276
Cancer-associated IDH1 mutations produce 2-hydroxyglutarateQ24320239
Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomasQ24610836
Identification of a CpG island methylator phenotype that defines a distinct subgroup of gliomaQ24612429
Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenasesQ24632807
Recurring mutations found by sequencing an acute myeloid leukemia genomeQ24634204
An integrated genomic analysis of human glioblastoma multiformeQ24648860
IDH1 and IDH2 mutations in gliomasQ24648948
Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cellsQ24648994
IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomasQ24656269
The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylasesQ27667409
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiationQ27684364
IDH2 mutations are frequent in angioimmunoblastic T-cell lymphomaQ27851701
An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells.Q27852141
Loss of NAPRT1 expression by tumor-specific promoter methylation provides a novel predictive biomarker for NAMPT inhibitorsQ27852577
Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cellsQ28504783
AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1Q28506431
IDH mutation impairs histone demethylation and results in a block to cell differentiationQ29305058
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiationQ29615366
Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagyQ29615616
Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxiaQ29616650
IDH1 mutation is sufficient to establish the glioma hypermethylator phenotypeQ29617457
AMP-activated/SNF1 protein kinases: conserved guardians of cellular energyQ29618101
Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alphaQ29619709
Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in VivoQ33630257
Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Q33804713
IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B studyQ33897586
Cancer-associated isocitrate dehydrogenase 1 (IDH1) R132H mutation and d-2-hydroxyglutarate stimulate glutamine metabolism under hypoxia.Q34140953
IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumoursQ34186353
5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft.Q34374136
Mutational analysis reveals the origin and therapy-driven evolution of recurrent gliomaQ34391844
Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolomeQ34602582
Analysis of the IDH1 codon 132 mutation in brain tumorsQ34873009
Glioma cells with the IDH1 mutation modulate metabolic fractional flux through pyruvate carboxylaseQ35268977
Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viabilityQ35621293
Reductive carboxylation supports growth in tumour cells with defective mitochondria.Q35683311
Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancerQ35842729
Cancer-associated isocitrate dehydrogenase mutations inactivate NADPH-dependent reductive carboxylationQ35922402
Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) activity by small molecule GMX1778 regulates reactive oxygen species (ROS)-mediated cytotoxicity in a p53- and nicotinic acid phosphoribosyltransferase1 (NAPRT1)-dependent mannerQ36052583
IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolismQ36948088
Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibitionQ37220129
(R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversibleQ37332185
Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.Q37381606
The small molecule GMX1778 is a potent inhibitor of NAD+ biosynthesis: strategy for enhanced therapy in nicotinic acid phosphoribosyltransferase 1-deficient tumorsQ37410764
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectorsQ37447217
Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.Q37613957
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigeneticsQ37734751
The NAD metabolome--a key determinant of cancer cell biologyQ38047182
Medicinal chemistry of nicotinamide phosphoribosyltransferase (NAMPT) inhibitorsQ38107280
Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype.Q38874166
Inhibition of mutant IDH1 decreases D-2-HG levels without affecting tumorigenic properties of chondrosarcoma cell lines.Q38884358
Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation.Q39394926
Identification of additional IDH mutations associated with oncometabolite R(-)-2-hydroxyglutarate productionQ39458545
Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.Q39636555
FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosisQ40617327
WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cellsQ40748736
Selective inhibition of mutant isocitrate dehydrogenase 1 (IDH1) via disruption of a metal binding network by an allosteric small moleculeQ41906201
Characterization of R132H mutation-specific IDH1 antibody binding in brain tumorsQ43244943
SDH5 mutations and familial paraganglioma: somewhere Warburg is smilingQ43280621
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.Q45953731
Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinomaQ48568468
CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivoQ73229795
IDH1 inhibitor shows promising early resultsQ86519666
P433issue6
P304page(s)773-784
P577publication date2015-12-01
P1433published inCancer CellQ280018
P1476titleExtreme Vulnerability of IDH1 Mutant Cancers to NAD+ Depletion
P478volume28

Reverse relations

cites work (P2860)
Q336987562-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity.
Q478464842-hydroxyglutarate-mediated autophagy of the endoplasmic reticulum leads to an unusual downregulation of phospholipid biosynthesis in mutant IDH1 gliomas
Q47123308A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
Q47989563Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1R132H-Induced Metabolic Liabilities
Q91736543Altered cellular metabolism in gliomas - an emerging landscape of actionable co-dependency targets
Q38961789Altered metabolite levels in cancer: implications for tumour biology and cancer therapy.
Q37534085An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma
Q55457331Association between mutant IDHs and tumorigenesis in gliomas.
Q50033966Beyond Brooding on Oncometabolic Havoc in IDH-Mutant Gliomas and AML: Current and Future Therapeutic Strategies.
Q89497288Beyond Energy Metabolism: Exploiting the Additional Roles of NAMPT for Cancer Therapy
Q55456962Biological Role and Therapeutic Potential of IDH Mutations in Cancer.
Q91775513CRISPR Editing of Mutant IDH1 R132H Induces a CpG Methylation-Low State in Patient-Derived Glioma Models of G-CIMP
Q64277360Cancer-associated mutation and beyond: The emerging biology of isocitrate dehydrogenases in human disease
Q58609746Cell surface Notch ligand DLL3 is a therapeutic target in isocitrate dehydrogenase mutant glioma
Q38405744Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair
Q64242985Cholesterol Metabolism: A Potential Therapeutic Target in Glioblastoma
Q46232869Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant IDH1.
Q38771020Correlation of immune phenotype with IDH mutation in diffuse glioma.
Q47169542Current trends in mouse models of glioblastoma.
Q53433176D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation.
Q61796395DNA demethylation is associated with malignant progression of lower-grade gliomas
Q99609760Development of Autophagy Signature-Based Prognostic Nomogram for Refined Glioma Survival Prognostication
Q52604402Double-barreled gun: Combination of PARP inhibitor with conventional chemotherapy.
Q92059824Effective targeting of NAMPT in patient-derived xenograft models of high-risk pediatric acute lymphoblastic leukemia
Q26741300Emerging therapeutic roles for NAD(+) metabolism in mitochondrial and age-related disorders
Q50782958Exploiting tumor vulnerabilities: NAD(+)-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies.
Q89534126Extracellular glutamate and IDH1R132H inhibitor promote glioma growth by boosting redox potential
Q90025515Friend or foe-IDH1 mutations in glioma 10 years on
Q91286849Functional and topographic effects on DNA methylation in IDH1/2 mutant cancers
Q57048305Genetic Abnormalities, Clonal Evolution, and Cancer Stem Cells of Brain Tumors
Q64056689Glioblastoma Stem- Cells, Metabolic Strategy to Kill a Challenging Target
Q47894744Glioma CpG Island Methylator Phenotype (G-CIMP): Biological and Clinical Implications
Q90642725Glucose Metabolism on Tumor Plasticity, Diagnosis, and Treatment
Q99564929Glutamine reliance in cell metabolism
Q90425302Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma
Q91934018IDH mutation in glioma: molecular mechanisms and potential therapeutic targets
Q28066926IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives
Q58738690IDH1 is intrinsically tumor-suppressive but functionally attenuated by the glutamate-rich cerebral environment
Q91643878Identification of Circulating Genomic and Metabolic Biomarkers in Intrahepatic Cholangiocarcinoma
Q90516025Illuminating NAD+ Metabolism in Live Cells and In Vivo Using a Genetically Encoded Fluorescent Sensor
Q42652909Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL.
Q91761588Inhibition of PARP Sensitizes Chondrosarcoma Cell Lines to Chemo- and Radiotherapy Irrespective of the IDH1 or IDH2 Mutation Status
Q38720863Inhibitor of Nicotinamide Phosphoribosyltransferase Sensitizes Glioblastoma Cells to Temozolomide via Activating ROS/JNK Signaling Pathway.
Q32173000Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Q57261202Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
Q50065686In Vivo Imaging of Glutamine Metabolism to the Oncometabolite 2-Hydroxyglutarate in IDH1/2 Mutant Tumors
Q33763540Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma
Q98778655Isocitrate dehydrogenase 1 mutation enhances 24(S)-hydroxycholesterol production and alters cholesterol homeostasis in glioma
Q58728288Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1
Q47605895Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
Q41247181Isocitrate dehydrogenases in physiology and cancer: biochemical and molecular insight
Q33642585Meat Intake and the Dose of Vitamin B3 - Nicotinamide: Cause of the Causes of Disease Transitions, Health Divides, and Health Futures?
Q92875529Metabolic Abnormalities in Glioblastoma and Metabolic Strategies to Overcome Treatment Resistance
Q99549175Metabolic Constrains Rule Metastasis Progression
Q52716898Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities.
Q91013912Metabolic rearrangements in primary liver cancers: cause and consequences
Q49835155Metabolism, Activity, and Targeting of D- and L-2-Hydroxyglutarates
Q49028007Metabolism: Totally addicted to NAD(.).
Q89758958Metastatic pheochromocytoma and paraganglioma: proceedings of the MEN2019 workshop
Q60907690Mitochondrial VDAC1 Silencing Leads to Metabolic Rewiring and the Reprogramming of Tumour Cells into Advanced Differentiated States
Q93333875Molecular Pathogenesis of Low-Grade Glioma
Q36805635Molecular Pathways: Isocitrate Dehydrogenase Mutations in Cancer
Q46594099Molecular and Genetic Determinants of Glioma Cell Invasion
Q92630717Mutant IDH1 Depletion Downregulates Integrins and Impairs Chondrosarcoma Growth
Q92328393Mutant IDH1 Differently Affects Redox State and Metabolism in Glial Cells of Normal and Tumor Origin
Q42259199Mutant IDH1 regulates the tumor-associated immune system in gliomas
Q64974414Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics.
Q48228203Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
Q37230411Myc-Driven Glycolysis Is a Therapeutic Target in Glioblastoma
Q60958368NAD Metabolism in Cancer Therapeutics
Q90284271NAD metabolic dependency in cancer is shaped by gene amplification and enhancer remodelling
Q89944614NAD- and NADPH-Contributing Enzymes as Therapeutic Targets in Cancer: An Overview
Q92860042NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer
Q95936527Nanomedicine-based immunotherapy for central nervous system disorders
Q33703205Nicotinamide metabolism regulates glioblastoma stem cell maintenance
Q92256258Nicotinamide phosphoribosyltransferase is a molecular target of potent anticancer agents identified from phenotype-based drug screening
Q47131402Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy
Q92380923OT-82, a novel anticancer drug candidate that targets the strong dependence of hematological malignancies on NAD biosynthesis
Q57796367Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Sells
Q61811738PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity
Q42580090PIK3CA mutant tumors depend on oxoglutarate dehydrogenase
Q87892601Parahydrogen-Based Hyperpolarization for Biomedicine
Q99240595Patient-derived cells from recurrent tumors that model the evolution of IDH-mutant glioma
Q41064782Perspectives on investigational drugs and immunotherapies for glioblastoma
Q52584624Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.
Q39417407Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts
Q51760444Pivotal role of NAMPT in the switch of melanoma cells toward an invasive and drug-resistant phenotype.
Q64972730Radiotherapy resistance in chondrosarcoma cells; a possible correlation with alterations in cell cycle related genes.
Q38757450Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis
Q46614710Reverse engineering the cancer metabolic network using flux analysis to understand drivers of human disease
Q90225264Sestrins as a Therapeutic Bridge between ROS and Autophagy in Cancer
Q93027996Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies
Q89486322Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate
Q38849515Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future
Q47646742Targeting Metabolism for Cancer Therapy.
Q52325957Targeting NAD+/PARP DNA repair pathway as a novel therapeutic approach to SDHB-mutated cluster I pheochromocytoma and paraganglioma.
Q38821103Targeting the cancer epigenome for therapy
Q46774124Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia
Q42511174The Alkylating Chemotherapeutic Temozolomide Induces Metabolic Stress in IDH1-Mutant Cancers and Potentiates NAD+ Depletion-Mediated Cytotoxicity
Q38658458The emerging role and targetability of the TCA cycle in cancer metabolism.
Q90574839The oncometabolite 2-hydroxyglutarate produced by mutant IDH1 sensitizes cells to ferroptosis
Q91843726Transcriptomic Analysis of Glioma Based on IDH Status Identifies ACAA2 as a Prognostic Factor in Lower Grade Glioma
Q39130440Understanding the Intersections between Metabolism and Cancer Biology
Q47713415Wild-type and mutated IDH1/2 enzymes and therapy responses.
Q90736012mTORC2/Rac1 Pathway Predisposes Cancer Aggressiveness in IDH1-Mutated Glioma